Etiology and management of recurrent implantation failure: A focus on intra-uterine PBMC-therapy for RIF
| Autor: | Mehdi Yousefi, Golshan Sheikhansari, Zahra Pourmoghadam, Amir Mehdizadeh, Shahla Danaii |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Infertility medicine.medical_treatment Immunology Fertilization in Vitro Bioinformatics Endometrium 03 medical and health sciences 0302 clinical medicine Pregnancy Decidua Immunology and Allergy Medicine Humans Embryo Implantation Treatment Failure Inflammation 030219 obstetrics & reproductive medicine In vitro fertilisation business.industry Uterus Obstetrics and Gynecology Hydroxychloroquine Immunotherapy medicine.disease Premature ovarian failure 030104 developmental biology medicine.anatomical_structure Reproductive Medicine Etiology Female Inflammation Mediators business medicine.drug |
| Zdroj: | Journal of reproductive immunology. 139 |
| ISSN: | 1872-7603 |
| Popis: | Infertility is one of the most common problems among couples worldwide. Recurrent pregnancy loss, premature ovarian failure, recurrent implantation failure and etc. are common high prevalence disorders in societies. We will review the definition, causes and treatment of recurrent implantation failure disorder in recent studies. Implantation refers to the attachment of the embryo to the endometrial luminal surface and recurrent implantation failure (RIF) is defined as the failure to achieve a pregnancy after transferring high-grade embryos through at least three in vitro fertilization (IVF) cycles to the endometrium. The embryo factors, maternal age, uterine factors, and multifactorial effectors have been considered as the causes of implantation failure. In this review, we aim to focus on immunological factors and cells such as pro-inflammatory cytokines and dendritic cells, macrophages, decidual and uterine NK cells, as well as Th-1 cells. There are different types of treatment according to the cause of RIF including aspirin and low-molecular-weight heparin therapy, immunosuppressive drugs, intravenous immunoglobulins, and hydroxychloroquine. Among immunological recurrent implantation failure therapy, we will discuss the intrauterine PBMC-therapy in detail. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect